Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B13 | Q7Z5P4 | 14/20 | 0.40 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.38 |
| ▸ | DUT | P33316 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5487196 | 0.77 | HSD17B13 (0.47) | HSD17B13 | |
| SCHEMBL254514 | 0.75 | DUT (0.56) | UPP1DUT | |
| SCHEMBL9120735 | 0.73 | HSD17B13 (0.40) | HSD17B13 | |
| SCHEMBL24665500 | 0.71 | HSD17B13 (0.44) | HSD17B13 | |
| SCHEMBL13060128 | 0.70 | KDM4E (0.51) | UPP1HTT | |
| SCHEMBL5610519 | 0.70 | HSD17B13 (0.43) | HSD17B13 | |
| SCHEMBL13947776 | 0.70 | HSD17B13 (0.43) | HSD17B13 | |
| SCHEMBL24114956 | 0.68 | PNP (0.41) | UPP1DUTHTTUSP2PNP | |
| SCHEMBL7595779 | 0.67 | HSD17B13 (0.41) | HSD17B13HTTTSHR | |
| SCHEMBL8845687 | 0.67 | FGFR1 (0.47) | UPP1USP2PNPTSHREDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| CN-101443021-A | Prevention and treatment of cancer and other diseases | ALT SOLUTIONS INC (US) | 2009-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | TERT, POLRMT, RNASE1 | HSD17B13 3503/4885UPP1 267/4885DUT 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.